- Tullow Oil proposed rights issue at price of 130p/shr
- Tullow will host a conference call for investors and analysts at 9.00 a.m. UK time Friday
- Rights issue is subject to shareholder approval
- Without proceeds of the rights issue, and under a worst-case scenario, company says there is the possibility it will breach its leverage covenant in its $3b RBL facility and $225m corporate debt facility for measurement period ending Dec. 31, 2017 and thereafter
- It is the company’s intention to refinance the RBL facilities in 2017 and as part of refinancing the company will seek to agree with lenders a covenant profile that will ensure it remains in compliance with the leverage covenant
- Deal underwritten by Barclays, JPMorgan acting as joint global coordinators and bookrunners; Morgan Stanley is joint bookrunner; BNP Paribas, Crédit Agricole CIB and SocGen are co-bookrunners; DNB Markets, ING, Natixis, Nedbank are co-lead managers
M
Closing Market Summary: Stocks Stall on ThursdayWednesday's bullish momentum lingered at the opening bell on Thursday, but the energy faded fast as investors came up short on reasons to extend the stock market's record high level. The S&P 500 and the Dow closed with losses of 0.2% and 0.1%, respectively, while the Nasdaq finished flat.
News from Washington did little to encourage the notion that tax reform will be a quick and easy process; President Trump's proposed budget was met with resistance and three House Republicans voted against the GOP health care bill in a committee vote, casting doubt on the legislation's chances on the floor of the House.
Crude oil also played into the cautious tone as the energy component failed to sustain yesterday's positive momentum, squandering a solid pre-market gain. WTI crude finished the day just above its flat line at $48.75/bbl while the energy sector (-0.6%) closed solidly lower.
Biotechnology names weighed on the health care space (-0.9%) after Biogen (BIIB 278.96, -13.68) shares were downgraded at both Morgan Stanley and Leerink Partners on Thursday morning. The company lost 4.7% while the iShares Nasdaq Biotechnology ETF (IBB 298.61, -3.78) tumbled 1.2%.
The rate-sensitive utilities sector (1.1%) fell all the way to the bottom of the day's leaderboard as selling pressure in the Treasury market left yields modestly higher; the benchmark 10-yr yield increased by four basis points to 2.54%.
Most of the remaining sectors finished lower, including industrials (-0.4%), materials (-0.6%), telecom services (-0.3%), and real estate (-0.3%). However, the financials and technology sectors, which together comprise around 35.0% of the broader market, offset most of the negative influence with gains of 0.3% and 0.2%, respectively.
The technology sector centered its advance around Oracle's (ORCL 45.73, +2.68) latest earnings report in which the company reported better than expected earnings, issued upbeat guidance, and increased its dividend. On the other hand, the financial sector's uptick was likely a belated response to yesterday's rate hike. Since the FOMC announcement, investors heard from the Bank of Japan, Swiss National Bank, and the Bank of England. All three held pat, underscoring the Fed's hawkish tilt when compared to other central banks.
The consumer discretionary (+0.1%) and consumer staples (+0.1%) sectors also performed relatively well, finishing just above their flat lines as retailers showed strength; the SPDR S&P Retail ETF (XRT 42.43, +0.13) closed higher by 0.3%. Homebuilders also helped the consumer discretionary sector, evidenced by the 1.9% increase in the iShares U.S. Home Construction ETF (ITB 32.52, +0.59). The strength followed the release of the February Housing Starts report, which came in roughly as expected.
In addition to Housing Starts, Thursday also saw Initial Claims, March Philadelphia Fed, and January JOLTS:
- Housing starts increased to a seasonally adjusted annualized rate of 1.288 million units in February, up from a revised 1.251 million units in January (from 1.246 million). The consensus expected starts to increase to 1.260 million units. Building permits decreased to a seasonally adjusted 1.213 million in February from a revised 1.293 million (from 1.285 million) for January. The consensus expected a reading of 1.251 million.
- The key takeaway from the report is that there was strength in the single-family sector for both starts and permits. Single-family starts increased 6.5% to 872,000 while single-family permits increased 3.1% to 832,000.
- The latest weekly initial jobless claims count totaled 241,000 while the consensus expected a reading of 242,000. Today's tally was below the unrevised prior week count of 243,000. As for continuing claims, they declined to 2.030 million from the revised count of 2.060 million (from 2.058 million).
- The key takeaway from this report is that initial claims continue to run at low levels that point to the likelihood of healthy nonfarm payroll gains in the Employment Situation Report for March.
- The Philadelphia Fed Survey for March declined to 32.8 from an unrevised 43.3 in February while economists polled by had expected a reading of 25.0.
- The key takeaway from the report is that the index has increased for eight consecutive months and remains comfortably above the 0.0 dividing line between expansion and contraction.
- The January Job Openings and Labor Turnover Survey showed that job openings increased to 5.626 million from a revised 5.539 million (from 5.501 million) in December.
On Friday, investors will receive February Industrial Production (consensus 0.2%) at 9:15 ET, while February Leading Indicators (consensus 0.5%) and the University of Michigan Sentiment Index for March (consensus 96.8) will cross the wires at 10:00 ET.
- Nasdaq Composite +9.6% YTD
- S&P 500 +6.4% YTD
- Dow Jones Industrial Average +5.9% YTD
- Russell 2000 +2.1% YTD
In reaction to disappointing earnings/guidance:
- GES -13.6%, ARTX -13.4%, TROV -8.6%, INO -6.8%, PLX -6.3%, CNAT -5.3%, CVRS -2.9%, INSY -2.8%
- KPTI -2.7%, TTNP -2.5%, BCEI -1.7%, GV -1.7%, KNDI -1.2%
- IPI -12% (prices a 43.54 mln share underwritten public offering of common stock for gross proceeds of about $52.3 mln)
- AVID -6.5% (Postpones conference call to discuss Q4 financial results)
- PEN -4.1% (Commences an underwritten public offering of 1.3 mln shares of its common stock)
- ELF -1.3% (Files for $175 mln offering of common stock by selling stockholders)
- BIIB -2.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- CIEN -1.6% (downgraded to Neutral from Buy at Goldman; removed from Conviction Buy List)
- SIRI -1.5% (downgraded to Hold from Buy at Wunderlich)
- MASI -1.2% (downgraded to Neutral from Overweight at Piper Jaffray)
- UTHR -1% (initiated with a Underperform at Credit Suisse)
In reaction to strong earnings/guidance:
- XCO +17.2%, GALE +15.3%, PRTO +11.8%, FRSH +11.7%, IDRA +11.5%,ALRM +10.3%, GPRO +10.2%, SKLN +8.2%, ITEK +7.2%
- JASO +6.6%, CLRB +6.2%, ORCL +6.2%, SAEX +5.8%, MCRB +5.2%, SNOA +4.8%, RMTI +3.6%, CPRX +3.2%, SYNC +3.2%
- WSM +3.1%, RTK +2.7%, CALL +1.9%, YRD +1.4%, EVOK +1.3%, BTG +1%
- KGC +1.2% (Confirms that it has received an unsolicited proposal from Virtu Financial (VIRT) for $18.50-$20.00 per share in cash)
- BBVA +4.3%, SAN +4.2%, ING +2.6%, DB +2.3%, CS +1.8%
- SWC +2.7%, AG +2.6%, BBL +1.8%, FCX +1.6%, BHP +1.5%, VALE +1.5%
- SSRI +1.4%, PAAS +1.4%, CLF +1.3%, GOLD +1%, AEM +1%
- HTBX +13% (receivse a 3 year, $982k grant from the Florida Department of Health 2016-17 Zika Research Grant Initiative to further develop and test gp96-based Zika vaccine)
- MCRB +5.2% (Seres Therapeutics and FDA reach agreement on key design elements of a new SER-109 Phase 2 study)
- CTSO +3.9% (enters into a partnership with Dr. Reddy's Laboratories (RDY) for the South African market)
- TLND +3.2% (upsizes and prices offering by selling shareholders of 3,289,662 ADSs at $28.50 per share)
- TSLA +3% (Announces offerings of $250 mln of common stock and $750 mln aggregate principal amount of convertible senior notes due in 2022 in concurrent underwritten registered public offerings)
- DO +2.3% (Updates on injunction vs. Petrobras (PBR) regarding the Ocean Valor)
- EXK +2.3% (announces that exploration drilling on the Terronera property)
- AMRN +2.2% (reports REDUCE-IT Cardiovascular outcomes study remains on schedule to reach onset of target final primary major adverse cardiovascular event near the end of 2017)
- BKS +1.7% (Board authorizes new stock repurchase program of up to $50 mln of its common shares)
- SPWR +1.7% (Enters into a Project Supply Agreement with Next Era Energy Resources
- SAP +1.4% (in sympathy with ORCL earnings)
- EQC +1.3% (Board adds $150 mln to buyback program)
- LC +3.2% (upgraded to Buy from Neutral at Guggenheim)
- GBT +2.6% (Initiated with an Overweight at Cantor)
- ABX +1.6% (upgraded to Outperform at RBC Capital Mkts)
- GG +1.6% (upgraded to Sector Perform at RBC Capital Mkts)
- DAL +1.3% (upgraded to Outperform from In Line at Evercore ISI)
- LITE +1.2% (upgraded to Neutral from Sell at Goldman)